transdermal glp-1 receptor agonist patch clinical trial Do Patches Really Work? Evidence and FDA-Approved Alternatives Clinical efficacy results from clinical

Published May 31, 2023

In a number of studies, GLP-1R agonists such as liraglutide, exenatide and lixisenatide can reduce neuroinflammation in AD models, thereby improving cognitive dysfunction (140, 141, 144148)

Reid CT, Tobin AM, Ahern T, OShea D, Kirby B

Read more: To view or add a comment, sign in A new study presented at the European Society of Cardiology Congress 2025, powered by Truveta Data from more than 200,000 patients, found: Early discontinuation was linked to higher cardiovascular risks

Abildgaard J, Ploug T, Pedersen AT, Eiken P, Pedersen BK, Holst JJ, et al

Dear Editor, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of drugs that have emerged in the treatment of patients with type 2 diabetes mellitus and obesity